Grozdani x107 M, Soboti x10d B, Biasizzo M, Sever T, Vidmar R, Vizovi x161 ek M, et al. Cathepsin L-mediated EGFR cleavage affects intracellular signalling pathways in cancer. Biol Chem. 2023;: pubmed publisher

Nakajima M, Tanaka K, Yoneshima Y, Yamashita S, Shibahara D, Iwama E, et al. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells. Biochem Biophys Res Commun. 2023;681:120-126 pubmed publisher

Matsuda K, Hirayama D, Hino N, Kuno S, Sakaue Sawano A, Miyawaki A, et al. Knockout of all ErbB-family genes delineates their roles in proliferation, survival, and migration. J Cell Sci. 2023;: pubmed publisher

Li M, Zhao Q, Liao J, Wang X, Liu L, Zhang X, et al. Dioscin inhibiting EGFR-mediated Survivin expression promotes apoptosis in oral squamous cell carcinoma cells. J Cancer. 2023;14:2027-2038 pubmed publisher

Tsutsumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, et al. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Lung Cancer. 2023;175:101-111 pubmed publisher

Kang J, Chun J, Hwang J, Pan C, Li J, Boese A, et al. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell Rep. 2022;41:111827 pubmed publisher

Wagner A, Galicia Andr xe9 s E, Teufl M, Gold L, Obinger C, Sykacek P, et al. Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR. Biochemistry. 2022;61:2049-2062 pubmed publisher

Prieto Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, et al. USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Mol Oncol. 2022;: pubmed publisher

Scaramuzzino C, Cuoc E, Pla P, Humbert S, Saudou F. Calcineurin and huntingtin form a calcium-sensing machinery that directs neurotrophic signals to the nucleus. Sci Adv. 2022;8:eabj8812 pubmed publisher

Troitskaya O, Novak D, Nushtaeva A, Savinkova M, Varlamov M, Ermakov M, et al. EGFR Transgene Stimulates Spontaneous Formation of MCF7 Breast Cancer Cells Spheroids with Partly Loss of HER3 Receptor. Int J Mol Sci. 2021;22: pubmed publisher

Lee C, Kim M, Kim D, Kim T, Kim S, Im S, et al. Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer. Cancer Res Treat. 2021;: pubmed publisher

Choe J, Watchmaker P, Simic M, Gilbert R, Li A, Krasnow N, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13: pubmed publisher

Song X, Tang W, Peng H, Qi X, Li J. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Invest New Drugs. 2021;: pubmed publisher

Chen Y, Wang R, Huang S, Henson E, Bi J, Gibson S. Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells. Cancers (Basel). 2021;13: pubmed publisher

Sun G, Chiuppesi F, Chen X, Wang C, Tian E, Nguyen J, et al. Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids. Cell Rep Med. 2020;1:100002 pubmed publisher

Arjuna S, Venkataram R, Dechamma P, Chakraborty G, Babu N, D Cruz A, et al. Non-invasive detection of EGFR mutations by cell-free loop-mediated isothermal amplification (CF-LAMP). Sci Rep. 2020;10:17559 pubmed publisher

Vaishnavi A, Scherzer M, Kinsey C, Parkman G, Truong A, Ghazi P, et al. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep. 2020;32:107994 pubmed publisher

Arjuna S, Chakraborty G, Venkataram R, Dechamma P, Chakraborty A. Detection of epidermal growth factor receptor T790M mutation by allele-specific loop mediated isothermal amplification. J Carcinog. 2020;19:3 pubmed publisher

Mondal G, Lee J, Ravindranathan A, Villanueva Meyer J, Tran Q, Allen S, et al. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathol. 2020;139:1071-1088 pubmed publisher

Wang M, LAW M, Davis B, Yaaghubi E, Ghilardi A, Ferreira R, et al. Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell Death Discov. 2019;5:153 pubmed publisher

Quintanal Villalonga Á, Molina Pinelo S, Cirauqui C, Ojeda Márquez L, Marrugal A, Suarez R, et al. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. J Thorac Oncol. 2019;14:641-655 pubmed publisher

O Farrell H, Harbourne B, Kurlawala Z, Inoue Y, Nagelberg A, Martinez V, et al. Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis. J Thorac Oncol. 2019;14:656-671 pubmed publisher

Kim D, Park S, Kim D, Jeong M, Noh J, Kwon Y, et al. Direct visualization of single-molecule membrane protein interactions in living cells. PLoS Biol. 2018;16:e2006660 pubmed publisher

Deygas M, Gadet R, Gillet G, Rimokh R, Gonzalo P, Mikaelian I. Redox regulation of EGFR steers migration of hypoxic mammary cells towards oxygen. Nat Commun. 2018;9:4545 pubmed publisher

Pan M, Schinke H, Luxenburger E, Kranz G, Shakhtour J, Libl D, et al. EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers. PLoS Biol. 2018;16:e2006624 pubmed publisher

Shin D, Jo J, Han J. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Mol Cancer Ther. 2018;17:2024-2033 pubmed publisher

Baktash Y, Madhav A, Coller K, Randall G. Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process. Cell Host Microbe. 2018;23:382-394.e5 pubmed publisher

Kim M, Wang W, Sánchez M, Coukos R, von Zastrow M, Ting A. Time-gated detection of protein-protein interactions with transcriptional readout. elife. 2017;6: pubmed publisher

Al Akhrass H, Naves T, Vincent F, Magnaudeix A, Durand K, Bertin F, et al. Sortilin limits EGFR signaling by promoting its internalization in lung cancer. Nat Commun. 2017;8:1182 pubmed publisher

Yu Q, Huang F, Zhang M, Ji H, Wu S, Zhao Y, et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients. Mol Med Rep. 2017;16:1157-1166 pubmed publisher

Song X, Qi X, Wang Q, Zhu W, Li J. A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Am J Cancer Res. 2017;7:1884-1898 pubmed

Hidaka N, Iwama E, Kubo N, Harada T, Miyawaki K, Tanaka K, et al. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer. 2017;108:75-82 pubmed publisher

Ferreira R, Wang M, LAW M, Davis B, Bartley A, Higgins P, et al. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Oncotarget. 2017;8:28971-28989 pubmed publisher

Xu Y, Wang X, Chen Y, Chen S, Yang X, Sun Y, et al. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer. Theranostics. 2017;7:974-986 pubmed publisher

Lee H, Khan S, Khaliqdina S, Altintas M, Grahammer F, Zhao J, et al. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1. J Biol Chem. 2017;292:732-747 pubmed publisher

Yang L, Ma T, Zhang J. GPRC5A exerts its tumor-suppressive effects in breast cancer cells by inhibiting EGFR and its downstream pathway. Oncol Rep. 2016;36:2983-2990 pubmed publisher

LAW M, Ferreira R, Davis B, Higgins P, Kim J, Castellano R, et al. CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res. 2016;18:80 pubmed publisher

Yeo S, Wen J, Chen S, Guan J. Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR/Stat3 and Tgf?/Smad Signaling. Cancer Res. 2016;76:3397-410 pubmed publisher

Ku B, Bae Y, Koh J, Sun J, Lee S, Ahn J, et al. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Invest New Drugs. 2016;34:407-15 pubmed publisher

Gabrysiak M, Wachowska M, Barankiewicz J, Pilch Z, Ratajska A, Skrzypek E, et al. Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. Oncol Rep. 2016;35:3151-8 pubmed publisher

Yim C, Sekula D, Hever Jardine M, Liu X, Warzecha J, Tam J, et al. G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program. Cancer Res. 2016;76:1204-13 pubmed publisher

Min H, Yun H, Lee J, Lee H, Cho J, Jang H, et al. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer. 2015;14:113 pubmed publisher

Ferreira R, Law M, Jahn S, Davis B, Heldermon C, Reinhard M, et al. Novel agents that downregulate EGFR, HER2, and HER3 in parallel. Oncotarget. 2015;6:10445-59 pubmed

Lau Y, Du X, Rayannavar V, Hopkins B, Shaw J, Bessler E, et al. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget. 2014;5:10503-17 pubmed

Nikolos F, Thomas C, Rajapaksa G, Bado I, Gustafsson J. ER? regulates NSCLC phenotypes by controlling oncogenic RAS signaling. Mol Cancer Res. 2014;12:843-54 pubmed publisher

Slanina H, Mündlein S, Hebling S, Schubert Unkmeir A. Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells. Infect Immun. 2014;82:1243-55 pubmed publisher

Wu X, Bhayani M, Dodge C, Nicoloso M, Chen Y, Yan X, et al. Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget. 2013;4:1388-98 pubmed

Dai H, Liu Z, Jiang W, Kuhn R. Directed evolution of a virus exclusively utilizing human epidermal growth factor receptor as the entry receptor. J Virol. 2013;87:11231-43 pubmed publisher

Vermeer P, Colbert P, Wieking B, Vermeer D, Lee J. Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex. Cancer Res. 2013;73:5787-97 pubmed publisher

Pires M, Hopkins B, Saal L, PARSONS R. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biol Ther. 2013;14:246-53 pubmed publisher

Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum C, et al. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012;14:R148 pubmed publisher

Whitsett T, CHENG E, Inge L, Asrani K, Jameson N, Hostetter G, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012;181:111-20 pubmed publisher

Chen F, LoTurco J. A method for stable transgenesis of radial glia lineage in rat neocortex by piggyBac mediated transposition. J Neurosci Methods. 2012;207:172-80 pubmed publisher

Hoover A, Strand G, Nowicki P, Anderson M, Vermeer P, Klingelhutz A, et al. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene. 2009;28:3960-70 pubmed publisher

Greulich H, Chen T, Feng W, Janne P, Alvarez J, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2:e313 pubmed